Sunday, November 1, 2026

Pfizer Stock Was Up By Over 3.18% Today Amid Immunization Plans

ViaNews Editorial Team

December 8, 2020

Pfizer Stock Was Up By Over 3.18% Today Amid Immunization Plans
The New York Stock Exchange ended the session with Pfizer jumping 3.18% to $42.56 on Tuesday while the New York Stock Exchange rose 0.26% to $14,392.50. Pfizer today's close was $42.56, 0.49% below its 52-week high of $42.77.

News about Pfizer today

Pfizer, astra shots to be combined in U.K. covid vaccine trials. According to today's article on Bloomberg Quint, "Even as it begins the first Covid immunizations with a shot from Pfizer Inc., the U.K. plans to test it in combination with another vaccine from AstraZeneca Plc." U.S. says it will meet vaccine need despite global Pfizer demand. According to today's article on Bloomberg Quint, "U.S. officials insisted they'll have enough Covid-19 vaccine doses to let most Americans get inoculated by next summer." U.k. begins rollout of Pfizer vaccine in a first for the west. According to today's article on The Wall Street Journal, "The U.K. became the first Western country to start distributing a Covid-19 vaccine to its population, rolling out a mass inoculation program that could provide a template for other countries, including the U.S.." Pfizer shot effective, safe, FDA staff says before meeting. According to today's article on Bloomberg Quint, "The coronavirus vaccine made by Pfizer Inc. and its German partner BioNTech SE is highly effective in preventing Covid-19." Pfizer vaccine’s effect on transmission still unknown, FDA says. According to today's article on Bloomberg Quint, "Pfizer Inc.'s Covid-19 vaccine prevents symptomatic cases of the virus, but it'™s not clear if the shot keeps the disease from being transmitted, U.S. Food and Drug Administration staff found in a report issued Tuesday."

Pfizer's Sales

Pfizer's sales growth is a negative 9.7% for the current quarter and a decline by 0.5% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 9.1% and a negative 8.8%, respectively.

Pfizer's Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer's Stock Top and Bottom Yearly Value

Pfizer's stock is valued at $42.56 at 16:39 EST, under its 52-week high of $42.77 and way above its 52-week low of $26.45.

Pfizer's Moving Average

Pfizer's value is way above its 50-day moving average of $36.41 and way higher than its 200-day moving average of $34.98.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com